Navigation Links
TapImmune to Participate in Two Upcoming Investor and Industry Conferences
Date:3/22/2017

JACKSONVILLE, Fla., March 22, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that it will participate in two upcoming Investor and Industry conferences.

Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company's business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, NY.  Additionally, Dr. Wilson will serve as a panelist during the conference's "Cancer Vaccines: Immuno-Priming and Tumor Antigens" panel discussion.

Continue Reading
TapImmune to Participate in the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, and the Oligonucleotide & Peptide Therapeutics Conference in Boston.
TapImmune to Participate in the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, and the Oligonucleotide & Peptide Therapeutics Conference in Boston.

Concurrently, Dr. John Bonfiglio, President and Chief Operating Officer of TapImmune, will provide an overview of the company's unique approach during a presentation titled "Synthesis, Purification and Formulation of a New T Cell Vaccine Using 5 Novel Proteins," during the S2 Oligonucleotide & Peptide Therapeutics Boston Conference in Boston, MA.

Event:Sachs' 5th Annual Cancer Biopartnering & Investment ForumDate: Tuesday, March 28, 2017Times: Company presentation: 10:35 am (Eastern Time)

Cancer vaccine panel discussion: 2:00 pm (Eastern Time)Location:The New York Academy of Sciences, New York, NY Event:S2 Oligonucleotide & Peptide Therapeutics Boston Conference Date: Wednesday, March 29, 2017Time: 1:30 pm (Eastern Time)Location:Royal Sonesta Boston, Cambridge, MA

The presentation of the Sachs' 5th Annual Cancer Biopartnering & Investment Forum will be webcast live and will remain available as an archive following the presentation.  To access the webcast, please visit the events page section of the TapImmune website at http://tapimmune.com/events/.

About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman's cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

Please visit the company's website at www.tapimmune.com for more details. 

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The company assumes no obligation to update the forward-looking statements.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-to-participate-in-two-upcoming-investor-and-industry-conferences-300427763.html


'/>"/>
SOURCE TapImmune, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients
2. TapImmune: Year End 2016 Update
3. TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine
4. TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016
5. TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016
6. TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
7. TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
8. TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
9. TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016
10. Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida
11. TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):